IsoPlexis Revenue and Competitors
Estimated Revenue & Valuation
- IsoPlexis's estimated annual revenue is currently $15.1M per year.
- IsoPlexis received $13.5M in venture funding in September 2017.
- IsoPlexis's estimated revenue per employee is $154,286
- IsoPlexis's total funding is $330.5M.
- IsoPlexis's current valuation is $325.3M. (January 2022)
Employee Data
- IsoPlexis has 98 Employees.
- IsoPlexis grew their employee count by -66% last year.
IsoPlexis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.2M | 1 | -80% | N/A | N/A |
#2 | $4.3M | 28 | 8% | N/A | N/A |
#3 | $9.8M | 66 | -11% | N/A | N/A |
#4 | $1.4M | 9 | 350% | N/A | N/A |
#5 | $16.6M | 107 | -23% | N/A | N/A |
#6 | $4.5M | 29 | -22% | N/A | N/A |
#7 | $1.7M | 11 | 57% | N/A | N/A |
#8 | $2.3M | 15 | -6% | N/A | N/A |
#9 | $0.3M | 4 | -43% | N/A | N/A |
#10 | $4M | 26 | 0% | N/A | N/A |
What Is IsoPlexis?
IsoPlexis, a venture-backed Yale-spinout company, is developing a diagnostic platform to accelerate immunology research and therapeutic development. In particular, we are developing critical solutions for the implementation of new therapeutic technologies. We are a multidisciplinary team of engineers, scientists, and software developers who thrive on scientific discovery and the development of life-changing therapeutic platforms.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$330.5M
Total Funding
98
Number of Employees
$15.1M
Revenue (est)
-66%
Employee Growth %
$325.3M
Valuation
N/A
Accelerator
IsoPlexis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Sales Operations | Reveal Email/Phone |
2 | Principal Scientist | Reveal Email/Phone |
3 | Software Engineering Manager | Reveal Email/Phone |
4 | Sr. Software Developer | Reveal Email/Phone |
5 | Sr. Chemist | Reveal Email/Phone |
6 | Project Manager | Reveal Email/Phone |
7 | Field Service Team Lead | Reveal Email/Phone |
8 | Sr. Software Development Manager | Reveal Email/Phone |
9 | Procurement Manager | Reveal Email/Phone |
10 | Principal Scientist | Reveal Email/Phone |
IsoPlexis News
BRANFORD, Conn., April 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (IsoPlexis), the Superhuman Cell Company,...
IsoPlexis noted that it sold 25 single-cell analysis instruments during the first quarter, bringing the total number of instruments placed to...
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022.
BRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Revenue of $4.2 million for the third quarter of 2021, an increase of ...
BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds fro ...
Other Companies in Branford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.5M | 132 | 6% | N/A |
#2 | $43.9M | 133 | N/A | N/A |
#3 | $37M | 137 | 10% | N/A |
#4 | $48.4M | 163 | 15% | N/A |
#5 | $29.5M | 179 | 1% | N/A |
IsoPlexis Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-08-12 | $0.3M | Undisclosed | Connecticut Innovations | Article |
| 2015-06-02 | $2.4M | Undisclosed | Article | |
| 2017-09-26 | $13.5M | B | Spring Mountain Capital | Article |